cbdMD, Inc. (YCBD) AI Stock Analysis

cbdMD, Inc., founded in 2015 as Level Brands, Inc. and headquartered in Charlotte, North Carolina, produces and distributes hemp-based cannabidiol wellness products. It markets human-focused items such as tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids under the cbdMD and cbdMD Botanicals brands. It also offers veterinarian-formulated pet tinctures, chews, and topicals under the Paw CBD brand. Products are distributed directly via e-commerce, on third-party websites, through wholesale partnerships, and across brick-and-mortar retailers nationwide.

Annual revenue decreased from $44.5M in FY2021 to $19.2M in FY2025, reflecting a 5-year revenue CAGR of -14.5%. Gross margin stood at 62.4% in FY2025, recovering from 54.0% in FY2023. Operating margin improved from -44.1% in FY2021 to -11.3% in FY2025, while net losses shrank from -$70.1M in FY2022 to -$2.0M in FY2025. Over the trailing twelve months, revenue reached $20.9M with an operating margin of -20.4% and net profit margin of -13.8%. For the latest quarter ended June 30, 2026, quarterly revenue growth rose 20.6% year-over-year.

As of June 30, 2026, cbdMD held $2.1M in cash and short-term investments alongside total debt of $2.2M, resulting in net debt of $93,925. The current ratio stood at 2.50, and debt-to-equity was 0.27 against shareholders' equity of $8.2M. In FY2025, operating cash flow was -$1.5M, free cash flow was -$1.6M, and capital expenditures were $184,175. The company's share count expanded by 710.2% over 5 years.

With a market cap of $4.0M and enterprise value of $5.2M, YCBD trades at a trailing P/E of 1.5x and a forward P/E of 714.3x, compared to the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its price-to-sales multiple is 0.2x versus the peer median of 4.1x, and EV/EBITDA is 63.9x compared to the peer median of 12.0x. Over the past year, the stock fell 66.1%, trailing the S&P 500 (SPY) return of 16.8%, and is down 99.9% over 5 years.

Consensus coverage consists of 1 Buy rating and no Hold or Sell ratings. The mean price target is $2.00, representing an implied upside of 461.8% over the last close of $0.36. For the fiscal year ending September 30, 2026, the estimated EPS is -$0.33 on revenue of $21.9M. For the next fiscal year, 1 analyst projects revenue of $28.6M and an EPS of -$0.19. The company beat EPS estimates in 1 of the last 4 quarters.

This page is an AI-written research summary of cbdMD, Inc. (YCBD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: YCBD income statement, YCBD balance sheet, YCBD key metrics, YCBD analyst forecast, YCBD chart. See the YCBD stock overview for the latest quote and news.